ANCA-associated vasculitis: trials for referral
103 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
103 trials shown
No phase1 site
Not yet recruitingChina
NCT07901764
MYTP01 for Immune-Mediated Diseases
Zhejiang Provincial People's Hospital
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/212 sites
RecruitingUnited States
NCT06733935
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Nkarta, Inc.
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT02257866
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07904806
Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 315 sites
RecruitingBrazil, Canada, France, Israel, India, Mexico
NCT06512883
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
AstraZeneca
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 341 sites
RecruitingArgentina, Austria, Belgium, Canada, France, United Kingdom
NCT07444567
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
AstraZeneca
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT06379646
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
China Immunotech (Beijing) Biotechnology Co., Ltd.
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT06978647
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
China Immunotech (Beijing) Biotechnology Co., Ltd.
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT07104721
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
China Immunotech (Beijing) Biotechnology Co., Ltd.
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT07123519
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
China Immunotech (Beijing) Biotechnology Co., Ltd.
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07556484
Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
Mayo Clinic
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govNo phase1 site
Not yet recruitingUnited Kingdom
NCT07859995
Qualitative Study With Focus Groups of People Living With ANCA-associated Vasculitis (AAV) and Clinicians, to Explore Different Perspectives on Shared Decision-making in AAV.
University of the West of England
Registry updated 6 Oct 2026
Registry record: ClinicalTrials.govPhase 483 sites
RecruitingCzechia, Denmark, Greece, Hungary, Poland, Romania
NCT06072482
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Amgen
Registry updated 30 Sept 2026
Registry record: ClinicalTrials.govPhase 12 sites
Not yet recruitingItaly
2025-522821-37-00
Basket trial for B-cEll driven severe auToimmunE and aLoimmune diseases (chronic Graft vErsUs host diseaSe) treated with anti-CD19 CAR T-cell thErapy
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Registry updated 29 Sept 2026
Registry record: EU CTISEarly Phase 11 site
RecruitingChina
NCT07301164
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Peking University Third Hospital
Registry updated 23 Sept 2026
Registry record: ClinicalTrials.govPhase 1/20 sites
Not yet recruiting
NCT06821659
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
Peking University Third Hospital
Registry updated 23 Sept 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingChina
NCT06828042
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Peking University Third Hospital
Registry updated 22 Sept 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingChina
NCT07746180
Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis
Chinese PLA General Hospital
Registry updated 15 Sept 2026
Registry record: ClinicalTrials.govEarly Phase 11 site
Not yet recruitingChina
NCT07389499
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Grit Biotechnology
Registry updated 11 Sept 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingItaly
NCT07815886
Benralizumab Effectiveness in EGPA
European EGPA Study Group
Registry updated 11 Sept 2026
Registry record: ClinicalTrials.govPhase 317 sites
RecruitingAustria, Belgium, Denmark, France, Italy, Netherlands
2025-523307-29-00
ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment
AstraZeneca AB
Registry updated 3 Sept 2026
Registry record: EU CTISPhase 2/32 sites
RecruitingUnited States
NCT07176546
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Robert Spiera, MD
Registry updated 2 Sept 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT07800871
FT839 in Autoimmune Diseases
Fate Therapeutics
Registry updated 2 Sept 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingGermany
2024-519592-26-00
Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)
Universitaetsklinikum Heidelberg AöR
Registry updated 1 Sept 2026
Registry record: EU CTISNo phase15 sites
RecruitingCanada, Germany, United Kingdom, Italy, United States
NCT00315380
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
University of Pennsylvania
Registry updated 28 Aug 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingFrance
NCT07251179
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
University Hospital, Strasbourg, France
Registry updated 20 Aug 2026
Registry record: ClinicalTrials.govPhase 1/21 site
Not yet recruitingGermany
2024-519491-60-00
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
Universitaetsklinikum Tuebingen AöR
Registry updated 14 Aug 2026
Registry record: EU CTISPhase 253 sites
RecruitingSwitzerland, Czechia, Germany, Denmark, Spain, France
NCT06047171
Rescue of Nephrons With ALE.F02 (RENAL-F02)
Alentis Therapeutics AG
Registry updated 14 Aug 2026
Registry record: ClinicalTrials.govPhase 364 sites
RecruitingChina
NCT07168161
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Registry updated 13 Aug 2026
Registry record: ClinicalTrials.govNo phase0 sites
Not yet recruiting
NCT07737470
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Assistance Publique - Hôpitaux de Paris
Registry updated 10 Aug 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- China38 open trials
- United States19 open trials
- France17 open trials
- Italy9 open trials
- Germany9 open trials
- Netherlands8 open trials
- Canada7 open trials
- United Kingdom6 open trials
- Poland5 open trials
- Austria5 open trials
- Denmark4 open trials
- Sweden3 open trials
- Brazil2 open trials
- Israel2 open trials
- India2 open trials
- Belgium2 open trials
- Czechia2 open trials
- Japan2 open trials
- Mexico1 open trials
- Argentina1 open trials
- South Korea1 open trials
- Hungary1 open trials
- Romania1 open trials
- Greece1 open trials
- Spain1 open trials
- Switzerland1 open trials
- Ireland1 open trials
- Iceland1 open trials
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
2 trials · 10 publications · ROR
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
3 trials · 21 publications · ROR
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
Nantes, France
0 trials · 7 publications · ROR
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
0 trials · 15 publications · ROR
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
Barcelona, Spain
0 trials · 20 publications · ROR
Dr. D. Y. Patil Medical College, Hospital and Research Centre
Pune, India
0 trials · 8 publications · ROR
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Paris, France
0 trials · 7 publications · ROR
Lancashire Teaching Hospitals NHS Foundation Trust
Preston, United Kingdom
0 trials · 9 publications · ROR
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Japan
0 trials · 17 publications · ROR
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
1 trials · 7 publications · ROR
University of North Carolina at Chapel Hill
Chapel Hill, United States
0 trials · 20 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
No phaseEnded 30 May 2026
Completed31 participants
NCT07712172
Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3
No phaseEnded 31 Mar 2026
Completed299 participants
NCT07591753
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)
No phaseEnded 23 Mar 2026
Phase 1Ended 14 Jan 2026
Phase 2Ended 31 Dec 2025
Completed60 participants
NCT03482479
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
No phaseEnded 15 Sept 2025
Completed201 participants
NCT05716334
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Phase 3Ended 5 Sept 2025
No phaseEnded 30 Jul 2025
No phaseEnded 20 Jun 2025
Completed107032 participants
NCT06488703
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Phase 1/2Ended 19 Mar 2025
No phaseEnded 6 Mar 2025
No phaseEnded 14 Feb 2025
Completed60 participants
NCT05894317
Vascular Access Complications for Therapeutic Apheresis in Nephrology
Phase 3Ended 31 Dec 2024
Completed159 participants
NCT01940094
The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
Phase 3Ended 23 Sept 2024
Completed98 participants
NCT03164473
Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.
No phaseEnded 18 Sept 2024
Completed48 participants
NCT03698071
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
Phase 3Ended 20 Dec 2023
Completed65 participants
NCT02108860
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
Not medical advice. fetched 4 Nov 2026